Pacira Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Pacira Biosciences Inc in the second quarter 2026?
Pacira Biosciences inc achieved a return on average equity (ROE) of 2.13 % in its second quarter 2026, this is above PCRX's average return on equity of -14.07%.
Pacira Biosciences Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $687 million

ROE has advanced compared to 0.73% in the first quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 59 other companies had a higher return on equity. While the total ranking for ROE unchanged, relative to the first quarter 2026 at no. 2240.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-11.32 %	-18.11 %	-10.95 %	-2.98 %	-
Y / Y Net Income Change	-	-39.4 %	-89.79 %	-	-
Net Income (TTM) in Millions	15	5	7	21	-127
Return On Equity (TTM)	2.13 %	0.73 %	0.95 %	2.8 %	-16.53 %
PCRX's Total Ranking	# 2240	# 2240	# 1284	# 1807	# 2446
Equity (TTM) in Millions	672	654	693	727	758
Seq. Equity Change	2.77 %	-5.66 %	-4.69 %	-4.03 %	-5.11 %
Seq. Net Income Change	59.57 %	78.13 %	-69.86 %	-	-

Back to PCRX Management Effectiveness >> PCRX's 5 Years Annual ROE >> Compare PCRX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 60
Sector	# 181
Overall	# 2240

Return On Equity Statistics
High	Average	Low
29.64 %	-14.07 %	-116.57 %
(Sep 30 2020)		(Dec 31 2013)

PCRX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	693	778	870	775	730
Y / Y Equity Change	-10.95 %	-10.55 %	12.27 %	6.11 %	17.87 %
Net Income in Millions	7	-100	42	16	42
Y / Y Net Income Change	-	-	163.72 %	-62.1 %	-71.15 %
Return On Equity	1.01 %	-12.79 %	4.82 %	2.05 %	5.75 %

Back to PCRX Management Effectiveness >> PCRX's 5 Years Annual ROE >> Compare PCRX ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 1.01 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PCRX's' Return on Equity at Yahoo Finance
PCRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PCRX's Competitors
Subscribers only: Roe for Pacira Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for PCRX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
National Vision Holdings Inc	5.71 %
Conmed Corporation	5.51 %
Pfizer Inc	4.91 %
Privia Health Group Inc	4.23 %
Becton Dickinson And Company	3.79 %
Alkermes Plc	3.72 %
Lifemd Inc	3.47 %
Lifestance Health Group Inc	3.39 %
Revvity Inc	3.27 %
Bio rad Laboratories Inc	3.15 %
Envista Holdings Corporation	3.08 %
Immucell Corporation	2.68 %
Surgery Partners Inc	2.63 %
Mimedx Group Inc	2.61 %
Cormedix Inc	2.18 %
Atricure Inc	2.14 %
Pacira Biosciences inc	2.13 %
Warby Parker Inc	2.06 %
Repligen Corp	1.98 %
Arvinas Inc	1.91 %
Waters Corporation	1.88 %
Omada Health Inc	1.84 %
Radnet Inc	1.42 %
Icu Medical Inc	1.41 %
Biomarin Pharmaceutical Inc	1.18 %
Staar Surgical Co	1.08 %
Champions Oncology Inc	0.94 %
Delcath Systems Inc	0.46 %

Date modified: 2026-09-26T06:58:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.